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Abstract
Background: Involving the end-users of scientific research (patients, carers and clinicians) in setting research
priorities is important to formulate research questions that truly make a difference and are in tune with the needs
of patients. We therefore aimed to generate a national research agenda for Juvenile Idiopathic Arthritis (JIA)
together with patients, their caregivers and healthcare professionals through conducting a nationwide survey
among these stakeholders.
Methods: The James Lind Alliance method was used, tailored with additional focus groups held to involve younger
patients. First, research questions were gathered through an online and hardcopy survey. The received questions
that were in scope were summarised and a literature search was performed to verify that questions were
unanswered. Questions were ranked in the interim survey, and the final top 10 was chosen during a prioritisation
workshop.
Results: Two hundred and seventy-eight respondents submitted 604 questions, of which 519 were in scope. Of
these 604 questions, 81 were generated in the focus groups with younger children. The questions were
summarised into 53 summary questions. An evidence checking process verified that all questions were unanswered.
A total of 303 respondents prioritised the questions in the interim survey. Focus groups with children generated a
top 5 of their most important questions. Combining this top 5 with the top 10s of patients, carers, and clinicians
led to a top 21. Out of these, the top 10 research priorities were chosen during a final workshop. Research into pain
and fatigue, personalised treatment strategies and aetiology were ranked high in the Top 10.
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Conclusions: Through this study, the top 10 research priorities for JIA of patients, their caregivers and clinicians
were identified to inform researchers and research funders of the research topics that matter most to them. The
top priority involves the treatment and mechanisms behind persisting pain and fatigue when the disease is in
remission.
Keywords: Juvenile idiopathic arthritis, Research priority setting, James Lind Alliance, Patient involvement,
Background
Juvenile Idiopathic Arthritis (JIA) is a heterogeneous
disease that is characterised by the occurrence of
arthritis of unknown origin lasting for more than 6
weeks, with an onset before the age of 16 years. It is
the most common chronic rheumatic disease in chil-
dren [1]. The health outcome for children and young
adults with JIA has significantly improved, however
unanswered questions still remain regarding the care
of these patients [1, 2]. Nevertheless, there is increas-
ing evidence that the needs raised by patients with
JIA, their caregivers and clinicians are not always
reflected by the subjects as studied in research pro-
grammes [3]. Importantly, various studies demonstrate
the importance of involving the end-users of know-
ledge in setting priorities for research to formulate re-
search questions that truly make a difference and are
in tune with the needs of patients [4, 5].
While the importance is widely acknowledged [6], still
little effort is made to include patients in the set-up of
JIA research. This is probably also aggravated by the fact
that it includes a paediatric population, and it is still not
exactly clear how to best include their voice [7–10]. A
recent systematic review on research priority setting in
paediatric chronic disease shows that only one in four
studies reported parents/caregiver involvement, and only
5% included children directly [7]. One of the studies that
directly involves children/adolescents in research priority
setting for rheumatic conditions was a study by Parsons
et al. They successfully involved young people (11–24
years) in research prioritisation by organising focus
groups [11]. The domains ‘basic science’ and ‘psycho-
social research’ were found to be most significant and
have the highest priority for research. Notably, they
showed that young people can discuss and prioritise
scientific research, despite them being relatively research
naïve. We aimed to interweave the advantages of such
focus groups with the broader, well-established
approach of setting research priorities of the James
Lind Alliance (JLA).
The JLA is a non-profit initiative, founded in 2004 in the
United Kingdom to bring patients, carers (caregivers, here:
mostly parents), and clinicians together in Priority Setting
Partnerships (PSPs) to set research priorities [12, 13]. They
have developed a methodological approach that has now
been used worldwide to generate about a hundred research
agendas. Following the JLA methodology, we aimed to con-
duct a nationwide prioritisation exercise for JIA in the
Netherlands [2]. The ultimate aim of this study is to guide
future JIA research and funding to the issues that matter
most to all directly involved.
Methods
Ethical considerations
The Medical Ethical Committee of University Medical
Centre Utrecht confirmed that this study was exempted
from the Medical Research Involving Humans Act
(WMO) (METC protocol number 18–721/C).
Set-up
This PSP was conducted in the Netherlands. The full
set-up is demonstrated in Fig. 1 and also described in a
protocol article in this journal [2, 14].
Initiating parties and steering group
The PSP was initiated by two Dutch patient associations
for JIA (the Dutch JIA patient and parent organisation
(JVN) and Youth-R-Well.com (YRW)), and two Dutch
professional organisations (the Dutch Society for Paedi-
atric Rheumatology (NVKR), and the Dutch Health Pro-
fessionals in Paediatric Rheumatology (NHPKR)). An
expert steering group was assembled to oversee all
phases of the project. This group consisted of young
adult JIA patients (n = 4), parents of JIA patients (n = 3),
paediatric rheumatologists (n = 3), an ophthalmologist
(n = 1), physical therapists (n = 2) and a nurse practi-
tioner (n = 1). Clinicians were recruited from 7 academic
centres in the Netherlands. They were selected to repre-
sent all different professions and all geographic regions
of the Netherlands. Most of them were members of the
abovementioned organisations. Our JLA advisor (KC)
had an advisory role throughout the whole process,
while the steering group had the authority to make all
important decisions within the framework and guiding
principles of the JLA.
Scope
Before starting the process, the scope of our PSP was
defined in agreement with the steering group. We chose
to keep our scope broad to include questions regarding
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Fig. 1 A flow chart of the priority setting process. This Priority Setting Partnership was initiated by the Dutch JIA patient and parent organisation
(JVN),Youth-R-Well.com (an association for young people with JIA), NVKR (the Dutch Society for Paediatric Rheumatology), and NHPKR (Dutch
Health Professionals in Paediatric Rheumatology). This chart demonstrates the steps that were taken to generate the research agenda
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prevention, aetiology, symptoms, diagnosis, treatment,
prognosis, health services, self-management and psycho-
social aspects. We explicitly made the commitment to
include lower educated carers and patients, and children
to be truly inclusive.
Different phases
Collecting questions The first step was to collect
relevant questions from patients, carers and clinicians
through a survey (December 2018–March 2019).
Patients and parents were recruited to participate via
patient organisations (e-mail and social media), and via
flyers distributed at all outpatient clinics for paediatric
rheumatology in the Netherlands. Clinicians were
recruited via professional organisations’ newsletters and
flyers were sent to them. Demographic details were ana-
lysed periodically to strive for equal representation of
age, education level and region. Recent JIA guidelines
were also searched for research recommendations. Ex-
tracted recommendations were added to the question
database. Focus groups and small (group-) interviews
were held with children (aimed 10–13 years) in an ex-
ploratory, conversation-like manner, guided by an expert
in child participation (among others, CD). In-depth re-
sults of the focus groups will be published separately
(Aussems et al., in preparation).
Analysing questions All questions were reviewed and
assessed whether they were in scope. Questions that
were identified out of scope were put on a separate list
which was agreed upon in a steering group meeting.
Next, the included questions were grouped into categor-
ies and keywords were allocated to them, to ease the
process of summarising. In a face-to-face meeting, the
steering group summarised the questions into summary
questions. A search in PubMed and PsycINFO (re-
stricted to the last 10 years) was conducted to ensure
that the question was unanswered. Publications were
found to be relevant if they included systematic reviews,
meta-analyses, randomised control trials (RCTs) or large
representative cohort studies following the JLA guide-
lines. Next, the steering group provided expert opinion
on the articles that were retrieved from this search and
made the final decision about whether or not the ques-
tion could be identified as already answered.
Interim priority setting survey Here, the goal was to
make a shortlist of 20–25 questions for the final work-
shop. Again, a survey was designed in which participants
could choose their Top 10 (October–December 2019).
Participants were recruited in the same way as during
the first survey. Furthermore, participants of the first
survey who left their contact details were e-mailed
directly. Younger children were asked to rank their top 5
during focus groups that were set up as small priority
setting workshops. Three separate top 10s, for patients,
carers and clinicians, were determined. Together with
the top 5 of the younger children, a final shortlist was
set – they all had an equal weight. This shortlist was
taken to the final workshop.
Final priority setting workshop Participants of the
workshop were invited from the steering group, through
professional connections and through the interim survey
(people who left their contact details were approached)
to be inclusive of the whole JIA community. Prior to the
workshop, participants were asked to individually priori-
tise the shortlist of questions. Through three rounds of
prioritisation in both smaller and larger groups, chaired
by trained facilitators using an adapted nominal group
technique, the final top 10 was agreed (February 2020).
Several observers were invited from a large patient advo-
cacy organisation, an insurance company, the Dutch So-
ciety for Paediatrics (NVK) and the Dutch Arthritis
Foundation. They did not take part in the discussions,
but were present to observe the process, become
inspired and learn from the discussions.
Process evaluation
An independent ethical process evaluation was con-
ducted by a bio-ethicist (KJ) in order to evaluate (the
inclusiveness of) the priority setting process. The bio-
ethicist was present during all steering group meetings,
the final workshop, and was included in all correspond-
ence regarding the research agenda. In-depth results of
this evaluation will be published separately (Jongsma
et al., in press).
Results
Initial survey
During the first phase of the process, a total of 604 ques-
tions were gathered. Of these 604, 506 were submitted
by 278 respondents through the survey: 141 patients
(50.7%), 88 carers (31.6%) and 49 health care profes-
sionals (17.6%). Demographic data are summarised in
Table 1. Responses were gathered from all academic
centres and geographic regions in the Netherlands. In
the online survey, 25.8% of the carers had finished a
lower and middle education. To lower the bar of partici-
pating, a hardcopy version of the survey was distributed
at outpatient clinics. On this hardcopy version 59% of
the respondents had lower and middle education (see
Table 2), demonstrating the additional value of distribut-
ing hardcopy surveys. The underrepresentation of youn-
ger patients in the online survey – no more than 23% of
responding patients were younger than 16 years –
underscored the significance of the focus groups. In total
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Table 1 Demographics of participants of the first and second survey
First survey Second survey
Respondents (number; %) Total 278 (100%) Total 303 (100%)
Patients 141 (50.7%) Patients 125 (41.3%)
Carers 88 (31.6%) Carers 136 (44.9%)
Clinicians 49 (17.6%) Clinicians 42 (13.9%)



























University 13 (9.2%) University 20 (16.0%
Other 7 (5.0%) Other 5 (4.0%)
Carers Primary
school
5 (5.7%) Carers Primary
school
13 (9.6%)
PSE 5 (5.7%) PSE 6 (4.4%)
SGSE 4 (4.5%) SGSE 12 (8.8%)












Other 3 (3.4%) Other 6 (4.4%)
Age of responding patient (mean;
range)
mean 17.6 (range 4–55) years mean 19..95 (range 10–52) years
JIA subtype of patient (number; %) Polyarticular JIA 93 (40.6%) Polyarticular JIA 110 (42.3%)
Oligoarticular JIA 57 (24.8%) Oligoarticular JIA 50 (19.2%)






Systemic JIA 18 (7.9%) Systemic JIA 31 (11.9%)
Don’t know 49 (21.4%) Don’t know 50 (19.2%)
Disease duration in years
(mean; range)
8.8 years (0–65 years) 9.0 years (0–45 years)
Uveitis (number; %) Yes 51 (22.2%) Yes 66 (25.3%)
No 174 (76.0%) No 189 (72.4%)
Don’t know 4 (1.7%) Don’t know 6 (2.3%)
Location of treatment centre (number;
%)
Groningen 72 (25.9%) Groningen 48 (15.8%)
Utrecht 49 (17.6%) Utrecht 51 (16.8%)
Nijmegen 10 (3.6%) Nijmegen 5 (1.7%)
Boxmeer 29 (10.4%) Boxmeer 31 (10.2%)
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24 children (17 girls and 7 boys, 9–16 years of age, suf-
fering from JIA between 4months to 9 years), partici-
pated in two focus groups and six (group-) interviews,
Together, they formulated 81 extra questions (Aussems
et al., in preparation). Furthermore, in the Dutch JIA
guideline 17 additional unanswered research questions
were found [15].
Analysis of evidence uncertainties
Of the 604 submitted questions, 519 were determined to
be in scope. Out of scope questions mostly related to
logistics of care (e.g. “Why can’t blood be drawn at the
GP’s office instead of at the hospital?”, or: “Do we have
to pay for orthopaedic shoes ourselves or does the insur-
ance cover it?”) or personal situations (e.g. “Which type
of JIA do I have?”) and could not be answered by
research. During a face-to-face meeting, the steering
group summarized the remaining questions into 53 sum-
mary questions.
An elaborate search in PubMed and PsycInfo showed
that none of the 53 questions was completely answered.
A full list of all the submitted questions, the 53 summary
questions, our search strategy for evidence checking and
the critical appraisal of the studies has been published
online [16].
Interim survey
Three hundred and three people chose their top 10 from
the 53 questions: 125 patients (41.3%), 136 carers
(44.9%) and 42 clinicians (13.9%). Two focus groups with
seven and nine children respectively (in total 9 girls and
7 boys, 10–15 years), and a subsequent group priority
setting discussion attended by six girls and five boys
from the focus groups, resulted in a top 5 of their most
important questions (Aussems et al. in preparation).
The 35 questions in the respective top 10s of patients,
carers, clinicians, and the top 5 of younger children
showed considerable overlap. One question – on fatigue
– was prioritised by all 4 groups. Four questions were
ranked in three top 10s. This resulted in a combined top
21. Table 3 shows how these 21 questions were ranked
in the different groups. Interestingly, the question “How
can JIA be cured?” was highly prioritised by patients and
carers, and ranked very low by the clinicians. The clini-
cians may have been less optimistic about the chances to
find a cure in the near future. Three questions in the
childrens’ top 5 – numbered 14, 16 and 19 in Table 3 –
were ranked much lower by the other three groups. This
illustrates the added value of the focus groups.
Final workshop
During the final priority setting workshop, on February
7, 2020, the top 10 was chosen (see Table 3). The work-
shop was attended by five patients, five parents of
patients, and ten clinicians (paediatric rheumatologists
(n = 3), an ophthalmologist (n = 1), physical therapists
(n = 2), nurses (n = 3), and a psychologist (n = 1)). Clini-
cians were recruited from all academic centres in the
Netherlands. The results of two rounds of discussions
Table 1 Demographics of participants of the first and second survey (Continued)
First survey Second survey
Amsterdam (Reade) 15 (5.4%) Amsterdam (Reade) 13 (5.0%)
Amsterdam (UMC) 10 (3.6%) Amsterdam (UMC) 13 (5.0%)
Leiden 10 (3.6%) Leiden 18 (6.9%)
Rotterdam 79 (28.4%) Rotterdam 82 (27.1%)
Maastricht 1 (0.4%) Maastricht 5 (1.7%)
Other 3 (1.1%) Other 37 (12.2%)
a Levels of education: PVSE Pre-vocational secondary education (in Dutch: VMBO), SGSE Senior general secondary education (in Dutch: HAVO), PUE Pre-university
education (in Dutch: VWO), SVE Secondary vocational education (in Dutch: MBO), HPE Higher professional education (in Dutch: HBO)
Table 2 Levels of education of carers responding to online vs.




Lower (n, %) 4 (6.1%) 6 (27.2%) 10 (11.4%)
Middle (n, %) 13 (19.7%) 7 (31.8%) 20 (22.7%)
Higher (n, %) 47 (71.2%) 8 (36.3%) 55 (62.5%)
Other (n, %) 2 (3.0%) 1 (4.5%) 3 (3.4%)
Total (n) 66 22 88
SECOND SURVEY
Education levela
Lower (n, %) 16 (17.2%) 3 (7.0%) 19 (14.0%)
Middle (n, %) 31 (33.3%) 21 (48.8%) 52 (38.2%)
Higher (n, %) 43 (46.2%) 16 (37.2%) 59 (43.4%)
Other (n, %) 3 (3.2%) 3 (7.0%) 6 (4.4%)
Total (n) 93 43 136
aLower indicates primary school, VMBO/MAVO (lower general secondary
education). Middle indicates HAVO (higher general secondary education), VWO
(A-levels/pre-university education) and MBO (intermediate vocational
education). Higher indicates HBO (higher vocational education) and university
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and ranking in three mixed groups were combined, and
discussed further in a final session. The participants
chose to merge the two summary questions on persona-
lised medicine and strategies to taper off medication (see
Table 3). All 20 attendees unanimously agreed on the
final Top 10.
The result of the discussions in the final workshop
broadly reflected the interim rankings. For both patients
and carers, 6 of the interim top 10 questions (60%) were
selected. For clinicians it was 80%. For the focus groups
2 out of 5 questions (40%) were part of the final top 10.
Importantly, question 9 of the final top 10 made it into
the list because a young adult patient advocated for it
during the final discussion, using the argument that it
was the children’s top priority. Evaluations from the
participants of the final workshop were very positive:
patients, carers and clinicians felt like their voice was
heard, that all voices mattered equally, and that the
atmosphere was very positive.
Discussion
This project has brought patients, caregivers and clini-
cians together in creating a research agenda for JIA
using the JLA method. This is one of the first times a
PSP has integrated the JLA approach with additional
focus groups with children to ensure involvement of
paediatric patients of all age categories. We found that
the number one research priority involved the cause and
care of pain and fatigue when the disease was in remis-
sion. This is in line with a qualitative study by Bromberg









1. Pain and fatigue are often present when the disease is in remission. How does this happen,
what can one do about it, and can one predict which patients will suffer from them?
3 10 1a
2. What is the best treatment plan for each individual patient? (e.g. start a biological directly,
which one, and what to do when the first one does not work and how can medication best
be tapered off? b)
42 28 7a
3. What is the best treatment plan for uveitis in JIA, and are there factors that predict its
effectiveness?
36 25 5
4. Why are children with JIA fatigued more quickly, what can be done about it, and how can
one best cope with the fatigue in daily life?
6a 6 1a 2
5. How does JIA develop and which factors influence this? 6a 5 24
6. How can the course (flares, extensions, cure) of JIA be better explained and predicted? 15 9 6
7. What is the influence of nutrition on JIA, and can a diet help? 2 2 7a
8. What are the short and long term side effects/consequences of the drugs taken for JIA? 8 1 10a
9. What is the influence of JIA on future opportunities regarding school results, work and
relationships?
9 11 20 1
10. What is the influence of sports and exercise on JIA and vice versa? 24 37 7a
11. What are the long term physical consequences of JIA? 1 3 10a
12. How can JIA be cured? 4 4 42a
13. Is there an association between JIA and other (autoimmune) diseases, and if yes, how can
one better understand this?
10a 8 42a
14. How can pain best be recognised and be treated (with medication), and what action can a
patient take him/herself?
32 30 29a 3
15. Which knowledge and skills are needed for patients and parents to achieve a healthy and
active lifestyle?
38 24 4
16. How can pills be manufactured in such a way that they are easy to take? (i.e. shape, color,
taste)
29 40 29a 4
17. How can children/adolescents with JIA can best be supervised regarding school/education
in order to minimize drop-out rates and absenteism?
10 15 10a
18. Is JIA inheritable, and if yes, in what way? 5 13 51
19. What is the best way to practice your favorite sport safely? 43 49 17 5
20. Are there any strategies in alternative medicine that can help alleviate health complaints of
JIA?
21 7 42a
21.b When and how can medication for JIA best be tapered off? 37 21 3
a Signifies that a question was ranked in joint place with another question
b Question 21 was merged into question 2 during the final workshop
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et al. that finds self-reported pain and fatigue are highly
common in children with JIA despite advances in treat-
ment strategies [17]. It is also highlighted to be an im-
portant research area by Palman et al. [18], along with
defining better predictors of remission states, which was
also part of our Top 10. The fact that these studies all
underline the same top research priority demonstrates
the importance of future research focusing on this. Next
to pain and fatigue, the aetiology of the disease remains
an important topic that was featured high in our Top 10
and also in a recent priority setting exercise in the
United States [19].
Moreover, our study exposed other important research
areas such as personalised treatment strategies, JIA-
associated uveitis, nutrition, long-term effects of drugs
taken for JIA and sports/exercise that were not directly
featured in other studies. This may be due to the wide
scope we defined for this project, as well as the easily ac-
cessible nature of the JLA method that may have led to
the collection of more widespread themes. The fact that
the questions do not only cover the healthcare setting
but also comprise more (psycho) social and educational
issues suggests funding for these topics can also be
sought from psychological, social and educational fund-
ing bodies.
One major strength of our study is the use of the sys-
tematic and transparent JLA method, which enhances
the validity of our results. Furthermore, our efforts to in-
clude younger children is a strength. We conducted
focus groups during the two phases of the process where
information was gathered, such that they truly had their
say in determining the most important topics. Two
questions of the children’s Top 5 made it to the final
Top 10 (see Table 3), which indicates the significant in-
fluence they had in the PSP.
A challenge in this study was the inclusiveness of
people with all educational backgrounds and age groups
throughout the survey phases. The input of patients and
parents in the steering group was very valuable. For ex-
ample, they thought of using a cartoon on the flyers and
in social media coverage to capture people’s attention. A
parent proposed the use of hardcopy questionnaires in
these phases, which improved the inclusion of respon-
dents with regard to education level, especially in the
first phase. For people with low digital skills, it might be
more difficult to formulate their own question, than to
choose from a list of questions.
In a subgroup analysis of the parent responses in the
prioritising phase, we found that the online and hard-
copy groups of parents showed overlap in their prior-
ities. The parents responding with paper and pencil did
not rank the question on alternative medicine that high.
Interestingly, they did prioritize two questions on school
and education (nrs 9 and 17), that were not prioritized
in the online parent group. This may have been related
to their own educational background.
In this light, it is important to realise that participants
of the final workshop consisted of a group of (predomin-
antly) white, articulate, higher educated people, despite
explicit efforts to include people with lower educational
backgrounds and other ethnicities. This may have
influenced which questions made it to the Top 10. This
is a typical tendency in survey research and was also
observed in other PSPs [20]. Future PSPs may want to
come up with and employ alternative strategies to
ensure equal representation of all members of society.
We also observed that more questions from the clini-
cians initial shortlist made it into the final Top 10 (see
Table 3). This may be due to the fact that clinicians are
more trained to give their opinion about these matters
than young people and parents. Nevertheless, all
attendees at the final workshop in the end unanimously
agreed on the final Top 10 as a list of shared priorities.
Formally, this Top 10 was generated in the
Netherlands, but we expect it also holds for other west-
ern countries. Now that the research agenda has been
set, it is important that it is now indeed implemented
with research funders and researchers. To achieve this,
we attempted to inform the whole JIA research commu-
nity in the Netherlands of this prioritisation exercise
from the start, and some of the research groups made
the commitment to truly incorporate the Top 10 in the
long-term vision of their research lines. In addition, we
have organised workshops with researchers, patients,
parents and clinicians to turn the relatively broad ques-
tions into research proposals that can be presented to
funding agencies. These workshops took place in the fall
of 2020. With these workshops, we hope to gather a
group of people that is truly committed to finding an-
swers to the research questions of the Top 10.
Conclusions
In short, we systematically and transparently generated a
research agenda for JIA, confirmed as evidence uncer-
tainties and regarded important by children and young
people with JIA, their parents/caregivers and the clini-
cians caring for them. This is a vital resource that con-
veys a clear message to both government funders and
charitable agencies, about which research topics should
have priority. The next step is to turn the questions into
research proposals. Workshops are currently being orga-
nised to this end.
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